{"analyses":[{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupDescription":"Emotional functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6651","paramType":"Odds Ratio (OR)","paramValue":"0.94","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.34","groupDescription":"Emotional functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9927","paramType":"Odds Ratio (OR)","paramValue":"1.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Emotional functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8209","paramType":"Odds Ratio (OR)","paramValue":"1.03","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.45","groupDescription":"Emotional functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6507","paramType":"Odds Ratio (OR)","paramValue":"1.07","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.67","groupDescription":"Emotional functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2596","paramType":"Odds Ratio (OR)","paramValue":"1.21","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.58","groupDescription":"Emotional functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6532","paramType":"Odds Ratio (OR)","paramValue":"1.09","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.45","groupDescription":"Emotional functioning, Completion Of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7592","paramType":"Odds Ratio (OR)","paramValue":"1.05","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.40","groupDescription":"Emotional functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7424","paramType":"Odds Ratio (OR)","paramValue":"0.93","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.19","groupDescription":"Emotional functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1912","paramType":"Odds Ratio (OR)","paramValue":"1.37","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.53","groupDescription":"Emotional functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5526","paramType":"Odds Ratio (OR)","paramValue":"0.83","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.52","groupDescription":"Emotional functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3609","paramType":"Odds Ratio (OR)","paramValue":"0.69","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.20","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.23","groupDescription":"Emotional functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7527","paramType":"Odds Ratio (OR)","paramValue":"0.80","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-100.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"75.44","groupDescription":"Emotional functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Proportion of Responders","paramValue":"-33.33"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","groupDescription":"Physical functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3177","paramType":"Odds Ratio (OR)","paramValue":"0.85","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupDescription":"Physical functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4184","paramType":"Odds Ratio (OR)","paramValue":"0.88","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.24","groupDescription":"Physical functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5710","paramType":"Odds Ratio (OR)","paramValue":"0.91","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","groupDescription":"Physical functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3973","paramType":"Odds Ratio (OR)","paramValue":"0.88","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.55","groupDescription":"Physical functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5163","paramType":"Odds Ratio (OR)","paramValue":"1.12","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.35","groupDescription":"Physical functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6897","paramType":"Odds Ratio (OR)","paramValue":"0.93","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupDescription":"Physical functioning, Completion Of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5735","paramType":"Odds Ratio (OR)","paramValue":"0.91","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","groupDescription":"Physical functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1414","paramType":"Odds Ratio (OR)","paramValue":"0.75","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.55","groupDescription":"Physical functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8655","paramType":"Odds Ratio (OR)","paramValue":"0.96","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.35","groupDescription":"Physical functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3017","paramType":"Odds Ratio (OR)","paramValue":"0.72","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.26","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Physical functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2325","paramType":"Odds Ratio (OR)","paramValue":"0.60","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.06","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.69","groupDescription":"Physical functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1717","paramType":"Odds Ratio (OR)","paramValue":"0.33","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-46.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"79.82","groupDescription":"Physical functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analsyis","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Proportion of Responders","paramValue":"16.67"},{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","groupDescription":"Global health status/QoL, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4745","paramType":"Odds Ratio (OR)","paramValue":"1.11","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.22","groupDescription":"Global health status/QoL, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5499","paramType":"Odds Ratio (OR)","paramValue":"0.92","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.29","groupDescription":"Global health status/QoL, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8436","paramType":"Odds Ratio (OR)","paramValue":"0.97","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","groupDescription":"Global health status/QoL, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5798","paramType":"Odds Ratio (OR)","paramValue":"1.09","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Global health status/QoL, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9094","paramType":"Odds Ratio (OR)","paramValue":"1.02","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.67","groupDescription":"Global health status/QoL, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4006","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","groupDescription":"Global health status/QoL, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4024","paramType":"Odds Ratio (OR)","paramValue":"0.88","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.41","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8796","paramType":"Odds Ratio (OR)","paramValue":"0.97","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.32","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4350","paramType":"Odds Ratio (OR)","paramValue":"0.83","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.56","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6225","paramType":"Odds Ratio (OR)","paramValue":"0.86","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.36","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.77","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5775","paramType":"Odds Ratio (OR)","paramValue":"0.80","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.07","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.94","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2343","paramType":"Odds Ratio (OR)","paramValue":"0.37","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-100.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.39","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0833","paramType":"Difference in Proportion of Responders","paramValue":"-66.67","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupDescription":"Role functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Superiority","nonInferiorityType":"SUPERIORITY","pValue":"0.6012","paramType":"Odds Ratio (OR)","paramValue":"0.93","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.11","groupDescription":"Role functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2291","paramType":"Odds Ratio (OR)","paramValue":"0.85","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.24","groupDescription":"Role functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6574","paramType":"Odds Ratio (OR)","paramValue":"0.94","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.35","groupDescription":"Role functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9217","paramType":"Odds Ratio (OR)","paramValue":"1.01","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","groupDescription":"Role functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7693","paramType":"Odds Ratio (OR)","paramValue":"0.95","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.31","groupDescription":"Role functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6470","paramType":"Odds Ratio (OR)","paramValue":"0.92","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupDescription":"Role functioning, Completion Of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6391","paramType":"Odds Ratio (OR)","paramValue":"0.93","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupDescription":"Role functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0892","paramType":"Odds Ratio (OR)","paramValue":"0.73","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","groupDescription":"Role functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0550","paramType":"Odds Ratio (OR)","paramValue":"0.65","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.88","groupDescription":"Role functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0168","paramType":"Odds Ratio (OR)","paramValue":"0.49","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.65","groupDescription":"Role functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0021","paramType":"Odds Ratio (OR)","paramValue":"0.29","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.17","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.80","groupDescription":"Role functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7817","paramType":"Odds Ratio (OR)","paramValue":"0.80","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-100.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"75.44","groupDescription":"Role functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"-33.33"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.41","groupDescription":"Social functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6646","paramType":"Odds Ratio (OR)","paramValue":"1.06","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","groupDescription":"Social functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8677","paramType":"Odds Ratio (OR)","paramValue":"0.98","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.38","groupDescription":"Social functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7670","paramType":"Odds Ratio (OR)","paramValue":"1.04","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.28","groupDescription":"Social functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7487","paramType":"Odds Ratio (OR)","paramValue":"0.95","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.68","groupDescription":"Social functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1882","paramType":"Odds Ratio (OR)","paramValue":"1.23","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.72","groupDescription":"Social functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3015","paramType":"Odds Ratio (OR)","paramValue":"1.21","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.32","groupDescription":"Social functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9059","paramType":"Odds Ratio (OR)","paramValue":"0.98","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.35","groupDescription":"Social functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7125","paramType":"Odds Ratio (OR)","paramValue":"0.93","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.07","groupDescription":"Social functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0947","paramType":"Odds Ratio (OR)","paramValue":"0.68","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupDescription":"Social functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0686","paramType":"Odds Ratio (OR)","paramValue":"0.58","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.17","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.86","groupDescription":"Social functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0175","paramType":"Odds Ratio (OR)","paramValue":"0.39","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.09","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.30","groupDescription":"Social functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3376","paramType":"Odds Ratio (OR)","paramValue":"0.46","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-100.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"23.34","groupDescription":"Social functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5637","paramType":"Difference in Proportion of Responders","paramValue":"-50.00","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6"},{"groupId":"OG001","value":"19.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7"},{"groupId":"OG001","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"423"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7"},{"groupId":"OG001","value":"27.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"414"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4"},{"groupId":"OG001","value":"32.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1"},{"groupId":"OG001","value":"34.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8"},{"groupId":"OG001","value":"32.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4"},{"groupId":"OG001","value":"30.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"366"}],"units":"Participants"}],"title":"Physical Functioning, Completion of Treatment/Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"28.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7"},{"groupId":"OG001","value":"31.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5"},{"groupId":"OG001","value":"27.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8"},{"groupId":"OG001","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"40.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"Role Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"38.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Role Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5"},{"groupId":"OG001","value":"45.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"401"}],"units":"Participants"}],"title":"Role Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1"},{"groupId":"OG001","value":"50.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"title":"Role Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0"},{"groupId":"OG001","value":"50.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"311"}],"units":"Participants"}],"title":"Role Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8"},{"groupId":"OG001","value":"51.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"233"}],"units":"Participants"}],"title":"Role Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4"},{"groupId":"OG001","value":"46.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Role Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0"},{"groupId":"OG001","value":"45.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1"},{"groupId":"OG001","value":"43.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1"},{"groupId":"OG001","value":"38.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"27.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"43.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1"},{"groupId":"OG001","value":"31.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"442"}],"units":"Participants"}],"title":"Social Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6"},{"groupId":"OG001","value":"32.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Social Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8"},{"groupId":"OG001","value":"38.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Social Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"41.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"Social Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5"},{"groupId":"OG001","value":"48.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Social Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Social Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6"},{"groupId":"OG001","value":"40.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Social Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7"},{"groupId":"OG001","value":"41.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2"},{"groupId":"OG001","value":"34.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"36.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2"},{"groupId":"OG001","value":"36.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1"},{"groupId":"OG001","value":"43.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7"},{"groupId":"OG001","value":"28.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"454"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3"},{"groupId":"OG001","value":"30.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3"},{"groupId":"OG001","value":"33.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"412"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6"},{"groupId":"OG001","value":"36.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8"},{"groupId":"OG001","value":"35.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3"},{"groupId":"OG001","value":"36.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7"},{"groupId":"OG001","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Emotional Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1"},{"groupId":"OG001","value":"27.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4"},{"groupId":"OG001","value":"37.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1"},{"groupId":"OG001","value":"33.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"34.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"31.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3"},{"groupId":"OG001","value":"34.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0"},{"groupId":"OG001","value":"31.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.5"},{"groupId":"OG001","value":"38.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5"},{"groupId":"OG001","value":"43.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"42.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5"},{"groupId":"OG001","value":"46.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0"},{"groupId":"OG001","value":"34.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"GHS/OoL, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6"},{"groupId":"OG001","value":"38.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2"},{"groupId":"OG001","value":"34.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"35.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0"},{"groupId":"OG001","value":"32.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 24 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"473"},{"groupId":"OG001","value":"473"}],"units":"Participants"}],"description":"Percentage of participants with clinical improvement, defined as \\>= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.","id":"OG000","title":"Placebo With Paclitaxel, Carboplatin and Bevacizumab"},{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG001","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"NUMBER","populationDescription":"PRO-evaluable population is defined as patients in the ITT population with a baseline and \\>=1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.","title":"Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}